Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 20.10 |
Low | 20.10 |
Bid | -- |
Offer | -- |
Previous close | 20.10 |
Average volume | -- |
---|---|
Shares outstanding | 189.13m |
Free float | 129.47m |
P/E (TTM) | 9.23 |
Market cap | 288.23m CHF |
EPS (TTM) | -0.1332 CHF |
Data delayed at least 15 minutes, as of Jun 28 2019 17:47 BST.
More ▼
Announcements
- Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
- New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024
- Amended terms of Idorsia’s 2024 convertible bonds become effective
- Idorsia announces financial results for the first half 2024
- Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call
- Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
- Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds
- Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds
- Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category
- Idorsia holds its Annual General Meeting of Shareholders
More ▼